Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Research Summary. . JAMA 2026 Mar 28:e263429. doi: 10.1001/jama.2026.3429.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Research Summary. JAMA 2026 Mar 28:e263429. doi: 10.1001/jama.2026.3429.
PMID: 41903216